Product Images Docetaxel

This is a description for NDC 62332-678-16, which is a 16ml multiple-dose vial containing Docetaxel Injection, USP, a cytotoxic agent for intravenous use only. Each mL of the injection contains 10 mg of Docetaxel, USP (anhydrous), 260 mg Polysorbate 80 NF, 4 mg Anhydrous Citric Acid USP, 23% viv Dehydrated Alcohol USP, g.s. with Polyethylene Glycol 300 NF. The injection is ready to add to an infusion solution, but the concentration should be checked prior to preparation. The package insert contains complete instructions. The injection should be stored between 20° to 25°C and protected from light. See insert for the usual dosage. The injection is manufactured for Alembic Pharmaceuticals, Inc. in Bedminster, NJ 07921, USA.*

This is a product description for a medication called Docetaxel Injection, USP. It is produced by Alembic Pharmaceuticals Inc. in Bemnstor, NJ, USA. The medication comes in a 2mL single-dose vial with a concentration of 20 mg/2 mL (10 mg/mL) and is intended for intravenous use only. The unused portion of the medication should be discarded. The medication should be added to an infusion solution after checking concentration. The package insert provides complete instructions for use. The medication is a cytotoxic agent and requires a prescription. The product should be stored at 20° to 25°C.*

This is a description of Docetaxel Injection, which is a cytotoxic agent for intravenous use only. It comes in an 8mL vial with a concentration of 10mg/mL and contains 80mg of Docetaxel per vial. The solution is ready to be added to an infusion solution after checking the concentration. The package insert contains complete instructions. The solution should be stored at 20° to 25°C and protected from light. The manufacturer is Mlembic Pharmaceuticals, and the dosage is specified in the insert.*

The text is describing Figure 10 which shows the overall survival K-M curve of two groups TPF (n=255) and PF(n=246) over a period of 72 months. The X-axis denotes survival time in months while the Y-axis represents the number of patents at risk. However, it is difficult to interpret the data shown here without the actual curve or context of what these groups represent.*

This is a plot of the TAX317 survival K-M curves for Docetaxel 75 mg/m² vs. best supportive care, showing the cumulative probability of survival over time. It shows that docetaxel has greater overall survival than the best supportive care.*

This is a description of figure 4 illustrating the TAX320 survival K-M curves for docetaxel 75mg/m² versus vinorelbine or ifosfamide control. The data shows different survival times in months for both treatments, with a Logrank p value of 0.13. The graph also presents a scale from 0 to 10 for survival time in months.*

This is a graph showing the Tax327 Survival K-M Curves measuring survival probability over a period of time in months. The graph has percentage marks from 0 to 10 on the y-axis and time marks ranging from 0 to 70 months on the x-axis. It is not possible to interpret the data without additional context.*

The text describes a graph or chart labeled as "Figure 7" which pertains to a study on Gastric Cancer called TAX325. The graph shows a K-M Curve of survival rates over time in months ranging from 0 to 24. The graph shows a survival rate of 100 at the beginning of the study, and recording for survival rate at 3, 6, 9, 12, 15, 18, and 24 months. The text seems to be an illustration to support the data obtained from the Gastric Cancer study.*